Curis (CRIS) investor relations material

Leadership and strategic focus

• Leadership team includes experienced executives with backgrounds in biotech and pharma, with recent additions in medical and development roles.

• Strategic focus is on advancing emavusertib, a novel IRAK4-FLT3 inhibitor, across hematologic malignancies and solid tumors.

Emavusertib clinical development and mechanism

• Emavusertib targets IRAK4 and FLT3 pathways, key drivers in CLL, NHL, AML, and MDS, offering dual pathway inhibition.

• Combination with BTKi in CLL and NHL provides deeper and more durable responses than BTKi alone, with potential for fixed-duration, all-oral therapy.

• In AML, dual blockade of IRAK4 and FLT3 addresses adaptive resistance to FLT3 inhibitors, showing higher response rates.

Clinical results and study designs

• In PCNSL, emavusertib plus BTKi achieved 27% ORR in BTKi-experienced and 63% ORR in BTKi-naïve patients, outperforming benchmarks.

• Early data in CLL, WM, and MCL show consistent activity; Phase 2 studies are ongoing or planned in larger subtypes.

• In mFLT3 AML, emavusertib achieved a 38% composite CR/CRh rate versus 21% for gilteritinib, with a registrational study planned.

• Clinical studies are designed for both accelerated and full approval, with endpoints including ORR and MRD negativity.